Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

PVL
Palvella TherapeuticsPVLA
——
Revvity logo
RevvityRVTY
——

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's accrued expenses and other liabilities?
Kodiak Sciences Inc (KOD) reported accrued expenses and other liabilities of $4.56M in Q1 2026.
How has Kodiak Sciences Inc's accrued expenses and other liabilities changed year-over-year?
Kodiak Sciences Inc's accrued expenses and other liabilities increased by 93.5% year-over-year, from $2.36M to $4.56M.
What is the long-term trend for Kodiak Sciences Inc's accrued expenses and other liabilities?
Over 2 years (2022 to 2025), Kodiak Sciences Inc's accrued expenses and other liabilities has grown at a 103.2% compound annual growth rate (CAGR), from -$2.25M to $9.28M.